Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Heim

Showing results (121-130 of 122) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 122 results.
Leukemia|July 22, 2022
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndromeJ J W M Janssen, B Löwenberg, M Manz, et al.
Leukemia|August 15, 2017
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsR Hehlmann, M Lauseker, S Saußele, et al.
Pageof 13

Showing results (121-130 of 122) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 122 results.
Leukemia|July 22, 2022
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndromeJ J W M Janssen, B Löwenberg, M Manz, et al.
Leukemia|August 15, 2017
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsR Hehlmann, M Lauseker, S Saußele, et al.
Pageof 13